Because of previously published data describing Gal-3 as an indicator of clear cell carcinomas, we measured the Gal-3 levels of patients with malignant (O-patients, low-grade endometrioid carcinoma) and benign gynecological tumors (G-patients, uterine and ovarian fibroids) at our tertiary referral center. Here, LGALS3 is linked to endometrioid adenocarcinoma.